Cross-protective efficacy of engineering serotype A @entity4021 virus vaccine against the two pandemic strains in XXXX .

@entity1707 @entity23012 @entity4021 @entity3689 @entity291
UNASSIGNED: @entity4021 ( @entity4021 ) is a highly contagious vesicular disease that affects domestic and wild cloven-hoofed animals worldwide. Recently, a series of outbreaks of type A FMDV occurred in Southeast Asian countries, China, the Russia Federation, Mongolia, Kazakhstan and South Korea. The @entity4021 virus (A/GDMM/ @entity23012 /2013) from China's Guangdong province (2013) is representative of those responsible for the latest epidemic, and has low @entity3689 identity (93.9%) in VP1 protein with the epidemic strain A/WH/ @entity23012 /09 from Wuhan, China in 2009. Both of isolates belong to the Sea-97 genotype of ASIA topotype. Therefore, the application of a new vaccine strain with cross-protective efficacy is of fundamental importance to control the spread of the two described pandemic strains. A chimeric strain rA/P1-FMDV constructed by our lab previously through replacing the P1 gene in the vaccine strain O/ @entity23012 /99 with that from the epidemic stain A/WH/ @entity23012 /09, has been demonstrated to exhibit good growth characteristics in culture, and the rA/P1-FMDV inactivated vaccine can provide protection against epidemic strain A/WH/ @entity23012 /09 in @entity291 . However, it is still unclear whether the vaccine produces efficient protection against the new pandemic strain (A/GDMM/ @entity23012 /2013). Here, vaccine matching and @entity1707 50% protective dose (PD50) tests were performed to assess the vaccine potency. The vaccine matching test showed cross-reactivity of sera from full dose vaccine vaccinated @entity1707 with A/WH/ @entity23012 /09 and A/GDMM/ @entity23012 /2013 isolates, with average r1 values of 0.94  0.12 and 0.68  0.06 (r1>= 0.3), which indicates that the rA/P1-FMDV vaccine is likely to confer good cross-protection against the two isolates. When challenged with two pandemic isolates A/WH/ @entity23012 /09 and A/GDMM/ @entity23012 /2013 strain, the vaccine achieved 12.51 PD50 and 10.05 PD50 per dose (2.8 g), respectively. The results indicated that the rA/P1-FMDV inactivated vaccine could protect @entity1707 against both A/WH/ @entity23012 /09 and A/GDMM/ @entity23012 /2013 pandemic isolates.
